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Jonathan Gray died yesterday. Five years ago, he under-
went an esophageal resection for cancer, developed an
aorto-esophageal fistula requiring an emergent colonic
interposition and survived to develop metastatic disease
to the liver, initially successfully treated with oxaliplatin
and a taxane containing regimen. Gifted with a sense of
life's meaning and purpose, a rather remarkable ability to
single out the best and brightest most capable of helping
him, he was a tireless enthusiast for making novel thera-
pies available to patients, and rallied against the futility of
the current drug development process – too slow, too
ineffective, and as he faced his own certain and early mor-
tality, impossibly oriented for the patient with cancer to
limited success for a limited number of individuals with
extraordinarily slow mechanisms.
Believing that an immune response was his best hope for
success, he visited and encouraged the tumor immunolo-
gists in the world that he felt were most capable of helping
him. I find myself fortunate in being one of those. In spite
of the extraordinary demands of his treatments over the
last few years, he persisted in making appeals to his
friends and colleagues to press the case for the urgency of
cancer research and rapid application of novel therapies.
With pain from a celiac plexus mass, a fungal infection in
trapped lung requiring multiple hospitalizations, and dif-
fuse metastatic hepatic disease, he rallied others to find
new strategies for cancer. For all of us who Jonathan con-
sulted, we are diminished by his passing, and furthermore
chastened to do more, imagine more, find more and
apply to others like him. He deserves no less.
All of us who work in the fields of cancer research and
therapy should applaud his vision, his magnanimity, and
devotion to what we hope will make the future scientists
and clinicians stand erect to take on the challenge of the
disease that ultimately took his life. We can indeed do
more, imagine more, find more and apply. Jonathan,
bless you and rest in peace. We are driven by your example
and your extraordinary hope. We too, like his remarkable
supportive family, are saddened by his passing, but pass
on his thoughtful reflections [with only modest editing]
on the needs he perceived but woefully too slow in
responding to his need to see his sons futures realized and
live for his parents and loved ones, just shy of his 60th
birthday. Jonathan, you live on in our hearts and dedica-
tion to delivering better therapies, more expeditiously,
and more effectively. Thank you for being there when we
needed you and for projecting your concerns on a recep-
tive oncologic audience. We are working now for others;
and of course want your just repose.
It's Cancer
Jonathan E. Gray
Manhattan, New York City, USA
Approximately 50% of all American men and 33% of all
women alive today are expected to be diagnosed with can-
cer, and just under 50% to die of their disease. This is the
current view of scientists and clinicians, and unlike the sit-
uation in cardiac disease, in which halving of mortality for
those dying under the age of 85 has been realized, cancer
therapy has only enjoyed minimal success and is now the
leading cause of death for those individuals.
Cancer is something that older people get, and I can
escape with a healthy diet, exercise and not smoking.
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Besides, there's a war against cancer, and probably hun-
dreds of billions of dollars and thousands of geniuses
doing research to cure the disease, with progress so rapid
they'll have it cured by the time I'm fifty. This may approx-
imate the more common, if subliminal, attitude.
Is the correct view one of optimism, or one of skepticism
and anger? This is a question on which experts will disa-
gree, and I am not an expert. I am a cancer patient. Yet,
even without exhaustive study, certain questions com-
mand immediate attention.
To begin with the obvious comparison, in 1941 in
response to a letter from Einstein, FDR created "The Man-
hattan Project," sparing no resources, and within thirty
months (and $20 billion in today's dollars) we detonated
the first atomic bomb.
In 1971, Nixon declared a "War on Cancer," with the
objective of finding a cure in five years. Thirty-five years
later, while enormous strides have been made in basic
biological science and technology, the actual "battle statis-
tics" are not that encouraging. There has been dramatic
success against pediatric cancer and blood malignancies,
but only meager success in treating solid tumors in adults,
of the breast, lung, colon, liver, kidney, pancreas, esopha-
gus and so forth. Early detection and surgery remain the
only hope for survival against these tumors. There are no
cures once the disease has metastasized, except in the rare
instance of melanoma and renal cell carcinoma in
patients treated with Interleukin 2.
Approximately 1.9 million Americans are diagnosed with
some form of cancer and 600,000 die of the disease annu-
ally. Aside from smoking related cancers, the incidence
has remained fairly stable on an age-adjusted basis for
decades.
Except for not smoking, the notion that by healthy living
one has significant control over the risk is exaggerated.
Cancer is a programming error, a software glitch in one's
genes. Mistakes, damage, mutations... arise naturally due
to copying errors when cells replicate.
Cells grow, divide and multiply. When the cell divides, it
copies its DNA so that each of the two resulting cells gets
an identical copy. These DNA molecules are millions of
molecules long, and consist of all the instructions for the
cell to function.
Now, while this copying is highly precise, with only about
1 molecule in a billion a mistake, we consist of hundreds
of trillions of cells, and over time, mutations accumulate.
And yet, it takes the unlikely occurrence of several muta-
tions in the same cell, generally 4 – 7, for it to become
malignant, dividing without cessation, traveling through-
out the body and invading normal organs instead of stay-
ing where it belongs. All it takes is one cell that evades the
surgeon's knife, or the radiation, or one's immune system,
and it's over. By the time the earliest cancers are detected,
at just 1 cm, no bigger than an orange seed, they already
consist of a hundred million malignant cells.
Cancer is a limit that nature has placed on a species whose
lifespan has increased! It's a disease that arises from a fail-
ure of your genes to control the behavior of your cells.
The analogy is made with a car whose gas-pedal is stuck
on the floor and it's just racing. Thank goodness for the
brakes! Now suppose the brake pedal gets stuck, and can-
not be depressed to stop the car, and the emergency brakes
and steering wheel fail. The threshold of 4–7 errors has
been reached, and the car is out of control.
The tremendous strides that have been made in basic sci-
ence are not readily applied to patients. Frequently physi-
cians are behind in their knowledge of the science, while
the scientists do not deal with patients. They deal with
mice. With all the hoopla over biotherapeutics, try to find
an immunologist to consult with your oncologist con-
cerning their use.
Most if not all tumor cells have special molecules on their
surface which identify the particular genes that have
failed. We should have been building a national data
bank, saving frozen pieces of tumors, testing them and
categorizing them into subsets based on their particular
tumor markers, and then checking which subsets of vari-
ous tumors respond to which therapies. Instead, tumor
tissue is rarely frozen, tested and the information saved
and studied. It's discarded as garbage! Or, the information
isn't shared between institutions, or there are software
incompatibilities, non-standardization of reagents, or, it
is guarded as intellectual property.
One can read of clinical trials for a new drug that targets a
particular marker, and even if your tumor bears the same
molecular target, you may not be permitted that drug.
Why? Because tumors are still categorized by their organ
of origin. If the drug is used to treat patients with
melanoma, never mind that your gastric tumor has the
same molecules, it's stomach cancer, not skin cancer.
At any point in time there are hundreds of thousands of
terminal cancer patients, with 3 months to live. Yet there
are always many experimental drugs that have passed
phase I and II tests for toxicity, and we know have no hor-
rible side effects. We just don't know how effective they'll
be, if at all. Well every one of these patients would give
anything for some hope, for a chance at an experimentalJournal of Translational Medicine 2007, 5:54 http://www.translational-medicine.com/content/5/1/54
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drug, particularly if the downside-risk were a skin-rash, or
diarrhea.
Moreover, scientists complain that research that works in
mice doesn't always work in humans. Yet, here's a chance
to work with human subjects where risks are manageable.
However, the drug companies are understandably reluc-
tant to provide experimental use of these drugs because
the liability attorneys are waiting to pounce on them.
Even if the patient signs a letter absolving everyone of lia-
bility, the courts may disregard it. The Congress should
address this situation immediately! Indeed, it may consti-
tute a violation of the 14th Amendment, as a deprivation
of life without due process of law.
Twenty five years ago, policy makers were upset that 10%
of US GDP was spent on healthcare, versus 6% in Europe.
So they decided to run healthcare like a business, with
HMOs, hospitals and insurance companies all squeezing
one another for profits. It was supposed to be more com-
petitive and efficient. Result? We now spend 15% of GDP
on our healthcare system, which ranks the US number
29th in the world, between Slovenia and Portugal, with
40% of the costs estimated to be duplicated administra-
tive expense.
Gifted scientists may spend one third of their time writing
grant proposals for the NCI instead of doing research.
I never could understand our national concern with
healthcare spending as a percent of our economy, pro-
vided it wasn't being wasted. The economy is simply what
we choose to do from 9 to 5 each day. Is it really preferable
to produce discretionary consumer goods, toys, than to
invest in our health? Many countries have healthy life-
spans that are 4 – 5 years longer than ours. Is it really
rational to prefer a consumer electronics device?
Why is a graduate in molecular biology offered four times
as much money to work on Wall Street as in a research
lab? Why is a potential research break-through, on which
thousands of lives may depend, delayed a year due to lack
of funding for an inexpensive technician? Why does an
Assistant Professor at a prestigious medical school earn
$60,000 while an NFL wide receiver earns $9,000,000?
These are not the kind of decisions Adam Smith believed
would be made optimally by "an invisible hand." The sys-
tem breaks down because of a lack of information on the
part of the voting public, and a culture geared toward the
production of consumers. And apparently, to some, it
doesn't really matter what we consume.
What would have happened if in 1941 FDR had given the
Manhattan Project to the free market and allowed hun-
dreds of companies to compete on a for-profit basis to
develop the bomb, and not to share information? We'd be
speaking German.
For Smith capitalism worked because market participants
could understand their choices and they had a choice
between competing goods that could be substituted for
one another. How many of us are equipped to discern
whether Genentech's Avastin or Pfizer's Sutent are better,
or helpful at all. As the ads relentlessly repeat, "Why not
ask your doctor if arsenic trioxide is right for you?" Unfor-
tunately many doctors have spent little time studying, and
biology has changed profoundly in the past 15 years.
One chemotherapeutic drug may add 3 months, another
5 months to survival that would be 15 months untreated,
and with virtually no prospect of a cure. There is enor-
mous revenue to be gained from market share, and always
at a meaningful increase in price. Is this really understood
by the public?
Cancer drugs are tested frequently as single agents, and
must be shown to be effective as such to be approved by
the FDA. Yet cancer is known to arise from multiple
genetic errors. Can multiple failures be repaired with only
one treatment mechanism? If we only got the steering
wheel fixed in that car, would the passengers have sur-
vived at high speed with no means to stop? Would it make
more sense to test cancer drugs in combinations, thera-
peutic cocktails, as has worked in AIDs? If so, how many
drugs that would have been effective in combination with
other drugs have instead been discarded over the past 35
years?
There are times when the war on cancer resembles more
of a traffic jam than a war. One is tempted to call for a
Manhattan Project in the war against cancer. Unfortu-
nately, there is little confidence in government, which
would likely just produce a more spectacular traffic jam. It
has been suggested that such a public effort on a grand
scale be directed by a politically independent agency,
something like the Federal Reserve Board, composed of
top scientists managers; perhaps we should create it.
In fact, the wealthiest amongst us, the top 1/2 of one per-
cent, literally have a surplus of money. They should,
according to Adam Smith, demand higher quality goods,
like a cure for breast cancer or prostate cancer, and added
years of life. However, if this can best be done with gov-
ernment intervention, they should lobby Congress to
impose a tax, so as to yield an incremental $15 billion or
so annually, initially, and increase this amount progres-
sively to perhaps $60 billion or more within a few years.
Ironically, real progress at reducing cancer would reduce
the total expenditures on health care and add meaning-Publish with BioMed Central    and   every 
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fully to the economy no matter how one measured
wealth.
So life goes on. You live a healthy, happy life for 45 – 65
years, and then it happens, the trap door opens beneath
you and you fall into a Kafkaesque, nether world, where
ultimately the patient is responsible for making a set of
choices that are dauntingly complex, expensive, and upon
which his life depends, while simultaneously dealing with
major surgery, chemotherapy and radiation, with nausea,
profound fatigue, and impaired mental focus.
The total expenditure on cancer research in the US is
approximately $15 billion annually, within the context of
a $1.8 trillion budget for government at all levels. This
includes just $4.75 billion at the NCI in 2007. Noncom-
mercial funding organisations in Europe collectively spent
$1.43 billion on cancer research 2002–2003. This ranged
from $388 million in the United Kingdom to $0 in Malta,
with only  three countries spending greater than $100 mil-
lion. In Euros the 3.6 billion for the US NCI is more than
two and a half times the 1.43 billion expended by  Euro-
pean noncommercial sources. The EU spends relatively
more on cancer biology than does the US (41% compared
with 25%). The US spends a greater proportion of its can-
cer research funding on research into prevention and
treatment than does the EU (prevention, 9% in the US
compared with 4% in the EU; treatment, 25% in the US
compared with 20% in the EU). In the US, the funding,
which has flattened in the last three years, is roughly
equivalent to what is spent annually on pet supplies and
car washes combined. Investment in cancer research is just
$51 per capita, as compared to per capita income of
$33,000. We still spend $290 per capita on tobacco prod-
ucts, and for those who are curious, $1,750 on defense.
Within the next decade, the average age of the U.S. popu-
lation will increase and lead to a large increase in annual
cancer incidence, perhaps 500,000 on top of the current
1.9 million cases, or 2.4 million, with annual deaths rising
250,000 to $850,000. Baby boomers, beware!
We will all be victims of cancer, whether as patients, or as
spectators to its destruction of those we love.
According to Leroy Hood of the Institute for Systems Biol-
ogy, significant progress against cancer may extend
healthy longevity by ten to thirty years. If the manufacture
of a car is measured in tens of thousands of dollars when
calculating GDP, how do we value life itself? Your
mother's, your husbands, your friend's, your own?
$51 per person per year toward cancer research out of
$33,000 in total per capita income! One sixth the price of
an iPod. A dramatic investment in cancer research and
clinical care seems urgently needed and long past due. It
is of secondary importance, but likely nonetheless, that
such an investment would bring handsome returns in
conventional economic terms as well. And finally, pray let
this cause be taken up in the interest of the public good of
all humanity, and not become a petty partisan squabble.
Note: Jonathan E. Gray was a securities analyst on Wall
Street with the firm of Sanford C. Bernstein & Co., special-
izing in research on financial companies for over thirty
years, until retirement for medical reasons. His demise
now gives us pause. Think again.